HCA

SEC source: 0001209191-17-014523 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,447.0681

F2 · kind: On February 5, 2014, the reporting person was granted 4,000 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 800 restricted stock units.

SEC source: 0001209191-17-014523 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,647.0681

F1 · kind: On February 6, 2013, the reporting person was granted 3,500 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 700 restricted stock units.

SEC source: 0001209191-17-014522 · doc4.xml · derivative · entry 5

Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100

Underlying: Common Stock · 1,100 shares

Expires 2024-02-05

F4 · balance_after: On February 5, 2014, the reporting person was granted 5,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,100 stock appreciation rights.

SEC source: 0001209191-17-014522 · doc4.xml · derivative · entry 4

Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common Stock · 1,400 shares

Expires 2023-02-06

F3 · balance_after: On February 6, 2013, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,400 stock appreciation rights.

SEC source: 0001209191-17-014522 · doc4.xml · nonDerivative · entry 3

Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,476

SEC source: 0001209191-17-014522 · doc4.xml · nonDerivative · entry 2

Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,662

F2 · kind: On February 5, 2014, the reporting person was granted 1,500 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 300 restricted stock units.

SEC source: 0001209191-17-014522 · doc4.xml · nonDerivative · entry 1

Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,362

F1 · kind: On February 6, 2013, the reporting person was granted 2,000 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 400 restricted stock units.

SEC source: 0001209191-17-014520 · doc4.xml · derivative · entry 6

Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common Stock · 1,400 shares

Expires 2024-02-05

F4 · balance_after: On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,400 stock appreciation rights.

SEC source: 0001209191-17-014520 · doc4.xml · derivative · entry 5

Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700

Underlying: Common Stock · 1,700 shares

Expires 2023-02-06

F3 · balance_after: On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,700 stock appreciation rights.

SEC source: 0001209191-17-014520 · doc4.xml · nonDerivative · entry 3

Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,357.0531

SEC source: 0001209191-17-014520 · doc4.xml · nonDerivative · entry 2

Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,715.0531

F2 · kind: On February 5, 2014, the reporting person was granted 2,000 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 400 restricted stock units.

SEC source: 0001209191-17-014520 · doc4.xml · nonDerivative · entry 1

Chari Ravi S. · CIK 0001632795 · SVP-Clinical Excellence

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,315.0531

F1 · kind: On February 6, 2013, the reporting person was granted 2,250 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 451 restricted stock units.

SEC source: 0001209191-17-014521 · doc4.xml · derivative · entry 2

Davis Jana Joustra · CIK 0001513409 · SVP - Corporate Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,500

Underlying: Common Stock · 3,500 shares

Expires 2024-02-05

F2 · balance_after: On February 5, 2014, the reporting person was granted 17,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 3,500 stock appreciation rights.

SEC source: 0001209191-17-014521 · doc4.xml · derivative · entry 1

Davis Jana Joustra · CIK 0001513409 · SVP - Corporate Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2023-02-06

F1 · balance_after: On February 6, 2013, the reporting person was granted 25,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,000 stock appreciation rights.

SEC source: 0001209191-17-014518 · doc4.xml · derivative · entry 8

CAMPBELL VICTOR L · CIK 0001216831 · SVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2024-02-05

F2 · balance_after: On February 5, 2014, the reporting person was granted 22,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 4,500 stock appreciation rights.

SEC source: 0001209191-17-014518 · doc4.xml · derivative · entry 7

CAMPBELL VICTOR L · CIK 0001216831 · SVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires 2023-02-06

F1 · balance_after: On February 6, 2013, the reporting person was granted 27,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,500 stock appreciation rights.

SEC source: 0001209191-17-014517 · doc4.xml · derivative · entry 4

JOHNSON R MILTON · CIK 0001216841 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,500

Underlying: Common Stock · 36,500 shares

Expires 2024-02-05

F2 · balance_after: On February 5, 2014, the reporting person was granted 182,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 36,500 stock appreciation rights.

SEC source: 0001209191-17-014517 · doc4.xml · derivative · entry 3

JOHNSON R MILTON · CIK 0001216841 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2023-02-06

F1 · balance_after: On February 6, 2013, the reporting person was granted 162,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 32,500 stock appreciation rights.

SEC source: 0001209191-17-030464 · doc4.xml · nonDerivative · entry 2

FRIST PATRICIA C · CIK 0001181963 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly through Hercules Holding II by Frist Children's Trust II

Disclosed balance after: 0

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Holdings, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist, Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Holdings, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein.

F2 · ownership.nature: The Reporting Person is the trustee of (i) Frist Children's Trust, (ii) Frist Children's Trust II and (iii) Patricia Champion Frist 2016 Grantor Retained Annuity Trust and may therefore be deemed to be the beneficial owner of the units of Hercules held by these trusts and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Holdings, Inc.

SEC source: 0001209191-17-030464 · doc4.xml · nonDerivative · entry 1

FRIST PATRICIA C · CIK 0001181963 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly through Hercules Holding II by Frist Children's Trust

Disclosed balance after: 0

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Holdings, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist, Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Holdings, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein.

F2 · ownership.nature: The Reporting Person is the trustee of (i) Frist Children's Trust, (ii) Frist Children's Trust II and (iii) Patricia Champion Frist 2016 Grantor Retained Annuity Trust and may therefore be deemed to be the beneficial owner of the units of Hercules held by these trusts and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Holdings, Inc.

SEC source: 0001209191-17-030463 · doc4.xml · nonDerivative · entry 2

FRIST THOMAS F JR · CIK 0000900596 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly through Hercules Holding II by Frist Children's Trust II

Disclosed balance after: 0

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Holdings, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist, Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Holdings, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F2 · ownership.nature: The Reporting Person's wife is the trustee of (i) Frist Children's Trust, (ii) Frist Children's Trust II and (iii) Patricia Champion Frist 2016 Grantor Retained Annuity Trust, and the Reporting Person may therefore be deemed to be the beneficial owner of the units of Hercules held by these trusts and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Holdings, Inc.

SEC source: 0001209191-17-030463 · doc4.xml · nonDerivative · entry 1

FRIST THOMAS F JR · CIK 0000900596 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly through Hercules Holding II by Frist Children's Trust

Disclosed balance after: 0

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Holdings, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist, Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Holdings, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F2 · ownership.nature: The Reporting Person's wife is the trustee of (i) Frist Children's Trust, (ii) Frist Children's Trust II and (iii) Patricia Champion Frist 2016 Grantor Retained Annuity Trust, and the Reporting Person may therefore be deemed to be the beneficial owner of the units of Hercules held by these trusts and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Holdings, Inc.

SEC source: 0001209191-17-030360 · doc4.xml · nonDerivative · entry 1

Frist William R · CIK 0001433377 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly through Hercules Holding II by Trusts for Children

Disclosed balance after: 3,911,150.4071

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Holdings, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist, Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Holdings, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F2 · ownership.nature: The Reporting Person's wife is the trustee of six trusts for the benefit of the Reporting Person's children, and the Reporting Person may, accordingly, be deemed to be the beneficial owner of the units of Hercules held by such trusts and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Holdings, Inc.

SEC source: 0001209191-17-030356 · doc4.xml · nonDerivative · entry 1

FRIST THOMAS F III · CIK 0001223892 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly through Hercules Holding II by Trusts for Children

Disclosed balance after: 2,348,330.3574

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Holdings, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist, Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Holdings, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F2 · ownership.nature: The Reporting Person may be deemed to be the beneficial owner of the aggregate (i) 28,489.62 units of Hercules held by certain trusts for the benefit of the Reporting Person's children, each of which his sister serves as trustee, and (ii) 2,348,330.3574 units of Hercules held by certain trusts for the benefit of the Reporting Person's children, each of which his wife serves as trustee, and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Holdings, Inc.

SEC source: 0001209191-18-010020 · doc5.xml · nonDerivative · entry 1

Elcan Patricia F · CIK 0001433376 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held indirectly by GRATs

Disclosed balance after: 3,410,250.975

F1 · ownership.nature: Hercules Holding II ("Hercules") holds 68,912,077 shares of the common stock of HCA Healthcare, Inc. Hercules is held by a private investor group, including affiliates of HCA Inc. founder Dr. Thomas F. Frist Jr. The Reporting Person may be deemed to be a member of a group exercising voting and investment control over the shares of common stock of HCA Healthcare, Inc. held by Hercules. However, the Reporting Person disclaims membership in any such group and disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein.

F2 · ownership.nature: The Reporting Person is trustee of three grantor retained annuity trusts for the benefit of her children, and the Reporting Person's spouse is the trustee of nine grantor retained annuity trusts for the benefit of the Reporting Person's children. The Reporting Person may, accordingly, be deemed to be the beneficial owner of the aggregate of 35,190 shares of common stock of HCA Healthcare, Inc. held by such trusts. In addition, the Reporting Person may be deemed to be the beneficial owner of the 3,466,416.4752 units of Hercules held by such trusts and therefore may be deemed to own indirectly the same number of shares of common stock of HCA Healthcare, Inc.

SEC source: 0001209191-17-014044 · doc4.xml · nonDerivative · entry 1

Davis Jana Joustra · CIK 0001513409 · SVP - Corporate Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,718

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.80 to $85.891, inclusive. The reporting person undertakes to provide to HCA Holdings, Inc., any security holder of HCA Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-17-012369 · doc4.xml · derivative · entry 3

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,750

Underlying: Common Stock · 2,150 shares

Expires 2021-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · derivative.exercise_date: The option vested in two equal annual installments beginning on November 2, 2014.

SEC source: 0001209191-17-012369 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,947.0681

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-17-012369 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,097.0681

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-17-010825 · doc4.xml · nonDerivative · entry 1

Riley Wayne Joseph · CIK 0001432895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,789

SEC source: 0001209191-17-014518 · doc4.xml · nonDerivative · entry 1

CAMPBELL VICTOR L · CIK 0001216831 · SVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,874

SEC source: 0001209191-17-010196 · doc4.xml · derivative · entry 13

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,252 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F6 · derivative.exercise_date: The option vested at the end of fiscal year 2009 based upon the achievement of certain annual EBITDA performance targets.

F3 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-010196 · doc4.xml · derivative · entry 12

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,252 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F3 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-010196 · doc4.xml · derivative · entry 11

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,504 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F5 · derivative.exercise_date: The option vested at the end of fiscal years 2010 and 2011 based upon the achievement of certain annual EBITDA performance targets.

F3 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-010196 · doc4.xml · derivative · entry 10

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,252 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F3 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-010196 · doc4.xml · derivative · entry 9

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,506 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F4 · derivative.exercise_date: The option vested in equal increments (i) at the end of fiscal year 2012 upon the achievement of certain annual EBITDA performance targets and (ii) upon a change in control (as defined in the 2006 Stock Incentive Plan for Key Employees of HCA Holdings, Inc. and its Affiliates as Amended and Restated) of the Issuer which occurred effective November 1, 2013.

F3 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-010196 · doc4.xml · derivative · entry 8

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,758 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F2 · derivative.exercise_date: The option was scheduled to vest in three equal annual installments beginning on August 27, 2012. A change in control of the Issuer occurred effective November 1, 2013, resulting in the accelerated vesting of the option as to the shares that remained unvested.

F3 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-010196 · doc4.xml · nonDerivative · entry 5

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 644

SEC source: 0001209191-17-010196 · doc4.xml · nonDerivative · entry 4

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,168

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-010196 · doc4.xml · nonDerivative · entry 3

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-010196 · doc4.xml · nonDerivative · entry 2

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-010196 · doc4.xml · nonDerivative · entry 1

Paslick P. Martin · CIK 0001551011 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,908

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-010195 · doc4.xml · nonDerivative · entry 1

Davis Jana Joustra · CIK 0001513409 · SVP - Corporate Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,060

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.50 to $83.62, inclusive. The reporting person undertakes to provide to HCA Holdings, Inc., any security holder of HCA Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-17-009234 · doc4.xml · derivative · entry 9

STEELE JOHN M · CIK 0001269276 · SVP - Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,010 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F6 · derivative.exercise_date: The option vested in equal increments at the end of fiscal years 2010 and 2011 based upon the achievement of certain annual EBITDA performance targets.

F4 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-009234 · doc4.xml · derivative · entry 8

STEELE JOHN M · CIK 0001269276 · SVP - Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,515 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F5 · derivative.exercise_date: The option was scheduled to vest in three equal annual installments beginning on August 27, 2012. A change in control of the Issuer occurred effective November 1, 2013, resulting in the accelerated vesting of the option as to the shares that remained unvested.

F4 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-009234 · doc4.xml · derivative · entry 7

STEELE JOHN M · CIK 0001269276 · SVP - Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,010 shares

Expires 2019-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Exercise Price was adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

F3 · derivative.exercise_date: The option vested in equal increments (i) at the end of fiscal year 2012 upon the achievement of certain annual EBITDA performance targets and (ii) upon a change in control (as defined in the 2006 Stock Incentive Plan for Key Employees of HCA Holdings, Inc. and its Affiliates as Amended and Restated) of the Issuer which occurred effective November 1, 2013.

F4 · derivative.underlying_shares: Shares have been adjusted to reflect a 4.505 to 1 stock split that occurred with respect to the Issuer's common stock effective March 9, 2011.

SEC source: 0001209191-17-009234 · doc4.xml · nonDerivative · entry 3

STEELE JOHN M · CIK 0001269276 · SVP - Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,783

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.495 to $82.68, inclusive. The reporting person undertakes to provide to HCA Holdings, Inc., any security holder of HCA Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-17-009234 · doc4.xml · nonDerivative · entry 2

STEELE JOHN M · CIK 0001269276 · SVP - Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,318

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-009234 · doc4.xml · nonDerivative · entry 1

STEELE JOHN M · CIK 0001269276 · SVP - Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,308

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-008466 · doc4.xml · derivative · entry 6

Wyatt Christopher F. · CIK 0001673365 · SVP & Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 564 shares

Expires 2023-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.